Relay Therapeutics

Motion-based drug design platform for precision cancer medicines.

PublicCambridge, MAFounded 2016

About

Relay Therapeutics uses its Dynamo platform, which integrates computational chemistry, biophysics, and machine learning, to design precision medicines based on how proteins move. The company focuses on developing small molecule cancer therapies targeting previously undruggable oncology targets. Its lead program targets specific FGFR2 mutations in cholangiocarcinoma and other cancers.

Total Funding

$770M

Key Product

RLY-4008 FGFR2-selective inhibitor

Geography

North America